Cellectar Files S-1 for $5.8M Warrant Resale Amid Regulatory Progress

TL;DR

**CLRB is diluting shareholders with warrant resales, but recent FDA and EMA progress on iopofosine I 131 offers a glimmer of hope for this cash-burning biotech.**

AI Summary

Cellectar Biosciences, Inc. (CLRB) filed an S-1 to register the resale of up to 2,096,188 shares of common stock by selling stockholders, stemming from a warrant inducement transaction that closed on October 8, 2025. This transaction generated approximately $5.8 million in gross proceeds for the company from the exercise of 1,048,094 existing warrants at $5.25 per share and the sale of new Inducement Warrants at $0.125 per warrant. The company will not receive proceeds from the resale of these shares, but will benefit from cash exercises of the Inducement Warrants. Recent developments include a July 2, 2025 public offering that raised approximately $6.9 million, and a June 5, 2025 warrant inducement yielding $2.5 million. Strategically, CLRB received Breakthrough Therapy Designation from the FDA on June 4, 2025, for iopofosine I 131 for relapsed/refractory Waldenstrom macroglobulinemia (r/r WM), and on October 6, 2025, the EMA's SAWP advised that a CMA filing for iopofosine I 131 for post-BTKi refractory WM patients could be acceptable, potentially leading to commercial availability in Europe by 2027. The company also effected a one-for-thirty reverse stock split on June 24, 2025, significantly impacting per-share metrics, with post-split basic net loss per share at $(4.20) for Q1 2025, compared to $(0.14) pre-split.

Why It Matters

This S-1 filing signals Cellectar's ongoing efforts to strengthen its balance sheet through warrant exercises, though the immediate resale by selling stockholders could introduce selling pressure on CLRB's stock, which closed at $4.50 on October 17, 2025. For investors, the influx of shares from the warrant inducement and previous offerings, alongside a recent 1-for-30 reverse stock split, creates a complex valuation landscape. The positive regulatory developments, including FDA Breakthrough Therapy Designation and EMA guidance for iopofosine I 131, are critical for the company's long-term prospects in the competitive biopharmaceutical market, particularly against other cancer treatment developers targeting Waldenstrom macroglobulinemia.

Risk Assessment

Risk Level: high — The company is a late-stage clinical biopharmaceutical company with no current revenue from drug sales, relying heavily on financing activities. The S-1 filing registers the resale of 2,096,188 shares, which could lead to significant dilution and downward pressure on the stock price. Furthermore, the company's post-Reverse Split net loss per share was $(4.20) for Q1 2025, indicating continued unprofitability and a high burn rate.

Analyst Insight

Investors should exercise extreme caution due to potential dilution from the 2,096,188 shares being registered for resale and the company's history of capital raises. While regulatory progress for iopofosine I 131 is positive, the path to commercialization is long and uncertain; consider this a highly speculative investment.

Financial Highlights

debt To Equity

Not Disclosed

revenue

Not Disclosed

operating Margin

Not Disclosed

total Assets

Not Disclosed

total Debt

Not Disclosed

net Income

Not Disclosed

eps

-$4.20

gross Margin

Not Disclosed

cash Position

Not Disclosed

revenue Growth

Not Disclosed

Key Numbers

• 2,096,188 Shares — Shares offered by selling stockholders (Represents potential dilution from warrant exercises and resales)
• $5.8 million — Gross proceeds from October 2025 warrant inducement (Cash infusion for the company from warrant exercises)
• $5.25 — Exercise price of Existing Warrants (Price at which 1,048,094 Existing Warrants were exercised)
• $6.00 — Exercise price of Inducement Warrants (Price for Series I and Series II Inducement Warrants)
• 1,048,094 shares — Shares from exercised Existing Warrants (Number of shares underlying the Existing Warrants exercised in October 2025)
• 1,048,094 shares — Shares underlying Series I Inducement Warrants (Potential future dilution from Series I Inducement Warrants)
• 1,048,094 shares — Shares underlying Series II Inducement Warrants (Potential future dilution from Series II Inducement Warrants)
• 1-for-30 — Reverse Stock Split ratio (Significantly reduced outstanding shares and increased per-share metrics on June 24, 2025)
• $4.20 — Post-Reverse Split Net loss per share, basic (Q1 2025) (Indicates continued unprofitability after the reverse stock split)
• 4,240,134 shares — Common stock outstanding as of June 30, 2025 (adjusted) (Reflects shares outstanding after recent offerings and warrant exercises)

Key Players & Entities

• Cellectar Biosciences, Inc. (company) — Registrant and biopharmaceutical company
• James V. Caruso (person) — President and Chief Executive Officer of Cellectar Biosciences, Inc.
• Sidley Austin LLP (company) — Legal counsel for Cellectar Biosciences, Inc.
• FDA (regulator) — Granted Breakthrough Therapy Designation for iopofosine I 131
• EMA (regulator) — European Medicines Agency, whose SAWP advised on CMA filing
• Ladenburg Thalmann & Co. Inc. (company) — Sole bookrunner for the July 2, 2025 public offering
• $5.8 million (dollar_amount) — Gross proceeds from October 8, 2025 warrant inducement
• $6.9 million (dollar_amount) — Gross proceeds from July 2, 2025 public offering
• $2.5 million (dollar_amount) — Gross proceeds from June 5, 2025 warrant inducement
• $4.50 (dollar_amount) — Last reported sale price of common stock on October 17, 2025

FAQ

Risk Factors

• Substantial Capital Requirements and Uncertainty of Future Funding [high — financial]: The company has a history of net losses and requires substantial capital for its research and development activities, including clinical trials for iopofosine I 131. Future funding is uncertain and dependent on successful capital raises, which may be impacted by market conditions and the company's stock performance. Failure to secure adequate funding could impede operations and development.
• Regulatory Approval Pathway and Timelines [high — regulatory]: The company's success hinges on obtaining regulatory approval for iopofosine I 131. While Breakthrough Therapy Designation was received from the FDA and positive feedback from the EMA's SAWP, the path to commercialization involves further clinical trials and regulatory reviews. Delays or failure to obtain approval in key markets like the US and Europe would significantly impact the company's prospects.
• Market Acceptance and Competition [medium — market]: The market for treatments for relapsed/refractory Waldenstrom macroglobulinemia (r/r WM) and other hematologic malignancies is competitive. The company must demonstrate the clinical efficacy and safety of iopofosine I 131 compared to existing and emerging therapies. Market adoption will depend on physician acceptance, patient outcomes, and pricing.
• Dependence on Key Personnel and Third-Party Manufacturers [medium — operational]: The company relies on a small team of key scientific and management personnel. The loss of any of these individuals could disrupt operations. Furthermore, the manufacturing of iopofosine I 131 involves third-party contract manufacturing organizations (CMOs), introducing risks related to quality control, supply chain disruptions, and adherence to manufacturing standards.
• Dilution from Future Stock Issuances [medium — financial]: The S-1 filing itself registers the resale of 2,096,188 shares from a warrant inducement transaction. The company also has outstanding options, warrants, and preferred stock convertible into common stock. Future exercises of these securities, or additional capital raises, could lead to significant dilution for existing shareholders, impacting per-share metrics.
• Post-Market Surveillance and Compliance [low — regulatory]: Even after potential approval, the company will be subject to ongoing regulatory scrutiny, including post-market surveillance, pharmacovigilance, and compliance with manufacturing and marketing regulations. Failure to meet these ongoing requirements could result in penalties or withdrawal of approval.

Industry Context

Cellectar Biosciences operates in the highly competitive oncology drug development sector, specifically focusing on rare hematologic malignancies. The market for relapsed/refractory conditions is characterized by unmet medical needs and a drive for novel therapies. Key competitors often include larger pharmaceutical companies with established R&D pipelines and significant market presence, as well as other biotechnology firms targeting similar indications. Regulatory pathways, such as the FDA's Breakthrough Therapy Designation, are critical for accelerating development and gaining market access.

Regulatory Implications

The company's primary regulatory focus is on obtaining marketing approval for iopofosine I 131. The FDA's Breakthrough Therapy Designation and the EMA's SAWP's positive feedback are significant milestones, but the path to commercialization involves rigorous clinical trials and adherence to strict manufacturing and safety standards. Post-approval, ongoing compliance with pharmacovigilance and regulatory reporting will be essential.

What Investors Should Do

1. Monitor clinical trial progress and regulatory updates for iopofosine I 131.
2. Assess the company's ability to secure future funding.
3. Evaluate the potential for shareholder dilution.
4. Consider the competitive landscape and market adoption potential.

Key Dates

• 2025-10-08: Warrant inducement transaction closed — Generated $5.8 million in gross proceeds for the company from warrant exercises and sale of new warrants.
• 2025-07-02: Public offering completed — Raised approximately $6.9 million, providing additional capital for operations and development.
• 2025-06-05: Warrant inducement transaction — Yielded $2.5 million in proceeds for the company.
• 2025-06-04: FDA Breakthrough Therapy Designation for iopofosine I 131 — Accelerates development and review process for a key drug candidate in r/r WM.
• 2025-06-24: One-for-thirty reverse stock split — Reduced outstanding shares, impacting per-share metrics and potentially improving stock price visibility.
• 2025-10-06: EMA SAWP advised CMA filing for iopofosine I 131 could be acceptable — Indicates potential for commercial availability in Europe by 2027, a significant market expansion opportunity.

Glossary

S-1 Filing

A registration statement filed with the U.S. Securities and Exchange Commission (SEC) by companies planning to offer securities to the public. (This document details the company's business, financial condition, risks, and the securities being offered, providing essential information for investors.)

Warrant

A security that gives the holder the right, but not the obligation, to purchase a company's stock at a predetermined price (exercise price) within a specified timeframe. (Warrants are a source of capital for the company when exercised, and their exercise can lead to dilution of existing shareholders' equity.)

Inducement Transaction

A transaction where a company offers warrants or other incentives to existing warrant holders to encourage them to exercise their warrants, often to raise capital or restructure debt. (The October 2025 warrant inducement transaction generated $5.8 million for CLRB and is the basis for the shares being registered for resale in this S-1.)

Breakthrough Therapy Designation

A designation granted by the FDA to a drug that is intended to treat a serious or life-threatening condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy. (This designation for iopofosine I 131 signifies potential for expedited review and development, increasing the likelihood of market approval.)

Reverse Stock Split

A corporate action in which a company reduces the number of its outstanding shares by consolidating them into a smaller number of shares. (CLRB executed a 1-for-30 reverse stock split on June 24, 2025, significantly reducing share count and increasing per-share metrics.)

Relapsed/Refractory Waldenstrom Macroglobulinemia (r/r WM)

A type of non-Hodgkin lymphoma where the cancer has returned after treatment (relapsed) or has not responded to treatment (refractory). (This is the specific indication for which iopofosine I 131 has received Breakthrough Therapy Designation.)

EMA's SAWP

The Scientific Advisory Working Party (SAWP) of the European Medicines Agency (EMA) provides scientific advice to the EMA on questions related to the quality, safety, and efficacy of medicinal products. (Their advice on the acceptability of a Marketing Authorisation Application (MAA) for iopofosine I 131 is a crucial step towards European market approval.)

Common Stock Outstanding

The total number of shares of a company's common stock that are currently held by all shareholders, including institutional investors and the public. (The number of outstanding shares is a key metric for calculating market capitalization and potential shareholder dilution.)

Year-Over-Year Comparison

This S-1 filing focuses on the resale of shares from a recent warrant inducement transaction and highlights significant progress in the development of iopofosine I 131, including FDA Breakthrough Therapy Designation and positive EMA feedback. Compared to previous filings, the company has successfully raised capital through recent offerings and warrant exercises, bolstering its cash position. However, the reverse stock split indicates a strategic move to address share price and potentially meet listing requirements, while the post-split net loss per share of $(4.20) for Q1 2025 underscores the ongoing financial challenges inherent in drug development.

Key Financial Figures

• $4.50 — rted sale price of our common stock was $4.50. Investing in our securities involves
• $5.25 — r common stock, at an exercise price of $5.25 per share, and pay $0.125 per new warra
• $0.125 — rcise price of $5.25 per share, and pay $0.125 per new warrant, in exchange for our ag
• $5.8 million — gregate gross proceeds of approximately $5.8 million from the exercise of the Existing Warra
• $6.00 — ely exercisable at an exercise price of $6.00 per share and will expire on October 8,
• $5.8 m — e Inducement Warrants was approximately $5.8 million, prior to deducting placement age
• $6.9 million — ing for gross proceeds of approximately $6.9 million prior to deducting underwriting commiss
• $5.00 — warrant. The price per class A unit was $5.00 and the price per class B unit was $4.9
• $4.99999 — 5.00 and the price per class B unit was $4.99999 (collectively, the July Offering). The
• $7.75 — arrants have an exercise price equal to $7.75 per share of common stock. The securit
• $9.123 — rrants), at a reduced exercise price of $9.123 per share. The shares of common stock i
• $2.5 m — une Existing Warrants was approximately $2.5 million, prior to deducting placement age
• $58.80 — 2029, and exercise prices ranging from $58.80 to $165.00 per share; 6 · an
• $165.00 — exercise prices ranging from $58.80 to $165.00 per share; 6 · an aggregate o

Filing Documents

• tm2529020d1_s1.htm (S-1) — 508KB
• tm2529020d1_ex5-1.htm (EX-5.1) — 10KB
• tm2529020d1_ex23-2.htm (EX-23.2) — 2KB
• tm2529020d1_ex-filingfees.htm (EX-FILING FEES) — 25KB
• tm2529020d1_ex5-1img001.jpg (GRAPHIC) — 5KB
• tm2529020d1_s1img001.jpg (GRAPHIC) — 9KB
• tm2529020d1_s1img002.jpg (GRAPHIC) — 37KB
• 0001104659-25-100854.txt ( ) — 737KB
• tm2529020d1_ex-filingfees_htm.xml (XML) — 5KB

Selected Financial Data

Selected Financial Data 5 The Offering 6

Forward-Looking Statements

Forward-Looking Statements 34

Use of Proceeds

Use of Proceeds 35 Dividend Policy 35 Determination of Offering Price 35 Selling Stockholders 36

Description of Securities to be Registered

Description of Securities to be Registered 38 Plan of Distribution 42 Legal Matters 44 Experts 44 Where You Can Find More Information 44 Information Incorporated by Reference 45 About This Prospectus You should rely only on the information contained or incorporated by reference in this prospectus and any applicable prospectus supplement. We have not, and the selling stockholders have not, authorized any other person to provide you with different or additional information. If anyone provides you with different or additional information, you should not rely on it. This prospectus is not an offer to sell, nor are the selling stockholders seeking an offer to buy, the shares offered by this prospectus in any jurisdiction where the offer and sale is not permitted. No offers or sales of any of the shares of our common stock are to be made in any jurisdiction in which such an offer or sale is not permitted. You should assume that the information contained in this prospectus or any applicable prospectus supplement is accurate only as of the date on the front cover thereof or the date of the document incorporated by reference, regardless of the time of delivery of this prospectus or any applicable prospectus supplement or any sales of the shares of our common stock offered hereby or thereby. You should read the entire prospectus and any prospectus supplement and any related issuer free writing prospectus, as well as the documents incorporated by reference into this prospectus or any prospectus supplement or any related issuer free writing prospectus, before making an investment decision. Neither the delivery of this prospectus or any prospectus supplement or any issuer free writing prospectus nor any sale made hereunder shall under any circumstances imply that the information contained or incorporated by reference herein or in any prospectus supplement or issuer free writing prospectus, as applicable. You should assume that the information appearing in t

Use of Proceeds

Use of Proceeds We will not receive any proceeds from the resale of the shares of common stock by the selling stockholders. See “Use of Proceeds” beginning on page 35 for additional information on the use of proceeds.

Risk Factors

Risk Factors See “Risk Factors” on page 9 and the other information included in this prospectus for a discussion of factors you should carefully consider before deciding whether to purchase our securities. Nasdaq symbol for common stock “CLRB” The number of shares of our common stock outstanding before and after this offering is based on 1,812,040 shares of common stock outstanding as of June 30, 2025, which is adjusted to 4,240,134 to give effect to 1,045,000 shares that were issued pursuant to the July Offering, 335,000 pre-funded warrants issued pursuant to the July Offering that have been exercised, and 1,048,094 shares that were issued pursuant to the exercise of the October Existing Warrants, and which excludes: · any shares of common stock issuable upon the exercise of the underwriter’s over-allotment option; · any shares of common stock issuable upon the exercise of Pre-Funded Warrants issued in this offering; · any shares of common stock issuable upon the exercise of Common Warrants issued in this offering; · any shares of common stock issuable upon the exercise of the representative warrants issued as compensation to the underwriter in this offering; · an aggregate of 211,816 shares of common stock issuable upon the exercise of outstanding stock options issued to employees, directors and consultants; · an aggregate of 13,040 shares of common stock issuable upon the conversion of outstanding shares of Series E-2 preferred stock; · an aggregate of 3,704 shares of common stock issuable upon the conversion of outstanding shares of Series D preferred stock; · an aggregate of 417,904 additional shares of common stock reserved for issuance under outstanding warrants having expiration dates between October 2027 and July 2029, and exercise prices ranging from $58.80 to $165.00 per share; 6 · an aggregate of 436,000 shares of common stock issuable upo

View Full Filing

View this S-1 filing on SEC EDGAR